Enveric Biosciences, Inc. insider trading

Every open-market purchase and sale by Enveric Biosciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Enveric Biosciences, Inc.’s insiders pay?

From July 27, 2012 to November 20, 2018, 9 insiders reported 16 open-market purchases and 3 sales not made under a pre-set plan in Enveric Biosciences, Inc. Twelve months after each purchase was reported, the shares were −45.3% against the S&P 500 on average (median −21.5%), over 11 purchases with a full year of prices; 18% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on December 11, 2015 into $536 by November 2, 2026, −23.6% a year. It held shares 27% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,051 (+5.6% a year), and held throughout $44,823 (+14.8%).

Copying Enveric Biosciences, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Enveric Biosciences, Inc.'s insiders from December 11, 2015, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 27% of the time.

Enveric Biosciences, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Lone Star Value Management LLC	Director	4	−17.8% (4)	50%	0	—	January 20, 2017
Eberwein Jeffrey E.	Chairman, President, CEO, CFO	3	−13.5% (1)	0%	0	—	February 2, 2016
Lone Star Value Investors Gp LLC	Director	3	−94.0% (3)	0%	0	—	October 31, 2017
Lone Star Value Investors LP	Director	3	−16.5% (2)	0%	0	—	November 21, 2017
Devanur Giri	President & CEO	1	—	—	1	—	July 19, 2018
Lone Star Value Co-Invest I, LP	Director	1	−98.1% (1)	0%	0	—	August 23, 2017
Rai Dhruwa N	Director	1	—	—	0	—	November 21, 2017
Schneider Greggory A	Chief Financial Officer	0	—	—	1	—	July 27, 2012
Sikaria Family 2008 Revocable Trust Dated 02/28/2008 and related entities	10% owner	0	—	—	1	—	November 20, 2018

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Enveric Biosciences, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Enveric Biosciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −32.7% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
September 29, 2017	2 buying	−59.1%	−83.0%	−96.6%
January 31, 2017	2 buying	−4.2%	−9.7%	−87.1%
December 31, 2015	2 buying	−18.4%	−5.4%	−13.4%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Enveric Biosciences, Inc. · Funds · Politicians